AMF Tjanstepension AB Purchases 45,292 Shares of Exact Sciences Co. (NASDAQ:EXAS)

AMF Tjanstepension AB increased its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 426.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,916 shares of the medical research company's stock after buying an additional 45,292 shares during the quarter. AMF Tjanstepension AB's holdings in Exact Sciences were worth $3,142,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Huntington National Bank grew its holdings in shares of Exact Sciences by 838.1% during the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company's stock valued at $27,000 after acquiring an additional 352 shares in the last quarter. RPg Family Wealth Advisory LLC acquired a new stake in Exact Sciences during the third quarter valued at $34,000. Capital Performance Advisors LLP acquired a new stake in Exact Sciences during the third quarter valued at $35,000. Asset Planning Inc purchased a new position in Exact Sciences in the fourth quarter valued at about $40,000. Finally, Modus Advisors LLC acquired a new position in Exact Sciences in the 4th quarter worth about $43,000. 88.82% of the stock is owned by institutional investors and hedge funds.

Exact Sciences Stock Performance

Shares of Exact Sciences stock traded up $0.46 during midday trading on Wednesday, hitting $46.35. The company had a trading volume of 1,524,746 shares, compared to its average volume of 2,329,750. The business's 50 day simple moving average is $52.45 and its two-hundred day simple moving average is $59.15. The stock has a market cap of $8.61 billion, a PE ratio of -8.32 and a beta of 1.25. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93. Exact Sciences Co. has a 1-year low of $40.62 and a 1-year high of $79.62.

Remove Ads

Exact Sciences (NASDAQ:EXAS - Get Free Report) last issued its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.23. The firm had revenue of $713.42 million during the quarter, compared to the consensus estimate of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. As a group, equities analysts predict that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on EXAS shares. BTIG Research lifted their price target on Exact Sciences from $65.00 to $75.00 and gave the company a "buy" rating in a report on Tuesday, November 26th. Piper Sandler decreased their target price on shares of Exact Sciences from $75.00 to $70.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. William Blair restated an "outperform" rating on shares of Exact Sciences in a research note on Thursday, February 20th. Scotiabank lifted their price objective on shares of Exact Sciences from $70.00 to $73.00 and gave the company a "sector outperform" rating in a research note on Monday, February 24th. Finally, Barclays decreased their price objective on shares of Exact Sciences from $70.00 to $65.00 and set an "overweight" rating for the company in a report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $71.94.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.